GlassScriptPhysician profile
Jeffrey L Weeks
NPI 1962613984
$2,115.82
in general payments reported to CMS, 2019-2025
20 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $307 · 2021: $258 · 2022: $577 · 2023: $226 · 2024: $357 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,075.03 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Glaukos Corporation | $267.96 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System, Idosetr |
| New World Medical,INC. | $229.31 | 2022-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Mayne Pharma Commercial LLC | $79.07 | 2021-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.34 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.31 | 2019-2020 | |
| Epi Health, LLC | $44.08 | 2022 | |
| Akorn Operating Company LLC | $43.88 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $43.79 | 2020-2021 | |
| Ucb, INC. | $36.91 | 2024 | Bimzelx |
| Ocular Therapeutix, INC. | $32.83 | 2022-2023 | Dextenza |
| Sun Pharmaceutical Industries INC. | $28.76 | 2023 | Ilumya |
| Bausch & Lomb Americas INC. | $17.65 | 2022 | |
| Leo Pharma INC. | $16.80 | 2025 | Adbry |
| Vyne Pharmaceuticals INC. | $16.02 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $14.96 | 2019 | |
| Allergan, INC. | $13.04 | 2021 | |
| Mission Pharmacal Company | $12.85 | 2019 | |
| Galderma Laboratories, L.P. | $12.10 | 2021 | |
| Aerie Pharmaceuticals, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.